The effectiveness of Atomoxetine generic in the treatment of ADHD was established in six randomized, double-blind, placebo-controlled studies in children, adolescents, and adults who met the criteria for ADHD, as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Of these six studies, four were used to assess the drug’s clinical [...]
Atomoxetine generic is supplied as capsules, in strengths of 10, 18, 25, 40, and 60 mg. For children and adolescents weighing up to 70 kg, the recommended initial dose is 0.5 mg/kg. After a minimum of three days, the dose should be increased to a targeted daily dose of 1.2 mg/kg. The targeted daily dose [...]
OVERVIEW In November 2002, the Food and Drug Administration (FDA) approved atomoxetine (Strattera generic, Eli Lilly) for the treatment of Attention-Deficit/Hyper-activity Disorder (ADHD), previously called Attention-Deficit Disorder. Atomoxetine is a potent inhibitor of the pre-synaptic norepinephrine transporter, with minimal affinity for other nor-adrenergic receptors or for other neu-rotransmitter transporters or receptors. Atomoxetine is thought to [...]
This was the first randomized study to directly compare OROS MPH and atomoxetine in African-American children. Response in this population was consistent with that observed in the overall population. Both treatments demonstrated significant improvement from baseline; however, improvements noted in the OROS MPH group were consistently greater than those observed in the atomoxetine group. Differences [...]
A total of 1,323 patients were enrolled in this study; of these, 183 were African-American (OROS MPH: n=125, ato-moxetine: n=58). The mean age of the total African-American group was approximately nine years, and most (87%) patients were male (Table 1). The treatment groups were well matched with regard to baseline disease characteristics. Adherence to study [...]
Patients Eligible children were 6-12 years of age with a diagnosis of ADHD based on psychiatric history and a review of the DSM-IV diagnostic checklist. Children must have scored >24 on the ADHD-RS at screening and must have been rated “moderately ill” or worse on the CGI-SI. Newly diagnosed treatment-naive patients and previously diagnosed patients [...]
The most studied and most often used stimulant medication for attention-deficit/hyperactivity disorder (ADHD) is methylphenidate (MPH). By 1996, there were 133 randomized, controlled trials describing the treatment of ADHD with MPH. However, MPH has a short duration of effect that results in a need for multiple daily dosing. Therefore, several long-acting formulations have been developed [...]
